# DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

> **NCT03237325** · PHASE3 · COMPLETED · sponsor: **Soligenix** · enrollment: 266 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
- Oral Mucositis

## Interventions

- **DRUG:** SGX942
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03237325
- **Lead sponsor:** Soligenix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-04
- **Primary completion:** 2020-06-24
- **Final completion:** 2021-06-24
- **Target enrollment:** 266 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03237325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03237325, "DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03237325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*